They could do it on their own if they chose. Biodel did. The real expensive cost and risk would be in distribution and marketing not to mention commercial supply, various device injectors and so forth. So its unlikely and would be a bad sign if they didn't license out pre phase III. LLY, Sanofi and Novo Nordisk are the 3 primary possibilities.
Since Cheetah was unveiled, Dr. Lim has stated consistently that they intend to use other income streams to finance their independent efforts to bring it to fruition. Your opinion that they can't do it is not based on any known facts at this point in time. I grant you that it is a potentially difficult proposition, but to say they can't overcome the hurdles is mere speculation. For now I'll give Dr. Lim the edge. -Fritz
Market Data 
Markets 
AI
